

1 **Using numerical modelling and simulation to assess the**
2 **ethical burden in clinical trials and how it relates to the**
3 **proportion of responders in a trial sample**

4 **SHORT TITLE**

5 Ethical loss in randomized clinical trials

6

7 Jean-Pierre Boissel^{1*}, David Pérol², Hervé Décousus³, Ingrid Klingmann⁴, Marc

8 Hommel⁵

9 **AFFILIATIONS**

10 ¹Novartis, Lyon, France, CSO, Emeritus Professor of Clinical Pharmacology

11 ²Department of Biostatistics, Centre Léon Bérard, Lyon, France, Head

12 ³INSERM, CIC 1408 - F Crin, INNOVTE; CHU Saint-Etienne, Hôpital Nord, Service

13 Médecine Vasculaire et Thérapeutique, F-42055 Saint Etienne, France, Head.

14 ⁴European Forum for Good Clinical Practice (EFGCP), Brussels, Belgium,

15 Chairwoman of the Board

16 ⁵University Hospital Grenoble, EA 4407 AGEIS UGA, France, Emeritus Professor of

17 Neurology

18 ***Corresponding Author**

19 E-mail: jean-pierre.boissel@novartis.com

20 These authors contributed equally to this work. All authors have reviewed the
21 manuscript

22 **ABSTRACT**

23 In order to explore how to reduce ethical losses in randomized controlled clinical
24 trials (RCTs), we set out to identify trial participants, including non-responders, who
25 do not contribute to demonstrating that the treatment in the experimental arm is
26 superior to that in the control arm. RCTs emerged mid last century as the gold
27 standard for assessing efficacy, becoming the cornerstone of the value of new
28 therapies, yet their ethical grounds are still debated. We introduce the concept of
29 unnecessary participants, defined as those included in RCTs considered not
30 informative with respect to efficacy, in contrast to responders who carry all the
31 information required to conclude on the treatment's efficacy. Non-informative
32 participants carry the burden of having to participate in a clinical trial without
33 benefiting from it, which might include experiencing side effects. Non-informative
34 participants can experience the outcome even if allocated to the experimental arm, or
35 not present it even if allocated to the control arm. Thus, these unnecessary participants
36 carry the ethical loss that is inherent to the RCT methodology. On the contrary,
37 responders to the experimental treatment bear its entire efficacy in the RCT. Starting
38 from the proportions observed in a real placebo-controlled trial from the literature, we
39 carried out simulations of RCTs progressively increasing the proportion of responders
40 up to 100%. We show that the number of unnecessary participants decreases steadily
41 until the RCT's ethical loss reaches a minimum. In parallel, the trial sample size
42 decreases (presumably its cost as well), although the trial's statistical power increases
43 as shown by the increase of the chi-square comparing the event rates between the two
44 arms. Thus, we expect that increasing the proportion of responders in RCTs would
45 contribute to making them more ethically acceptable, with less false negative
46 outcomes.
47

48 INTRODUCTION

49 The randomized controlled clinical trial (RCT) remains the gold standard for
50 evaluating the efficacy and safety of new therapies.[1,2] Despite their wide
51 acceptance, questions have been raised about the ethics of randomizing participants to
52 conventional treatments when deemed less effective, to placebo, or to an inadequate
53 treatment if the therapy tested turns out to be less effective or potentially harmful.
54 Although not specific to RCTs, subjecting study participants to a setting that differs
55 from that of the standard of care can signify a burden, often adding up to an additional
56 ethical issue. The required informed consent is usually presented as a global answer
57 [3] to these issues, but it merely transfers concerns from investigators to participants.
58 Several alternatives to traditional RCTs have been proposed recently to address some
59 of these ethical concerns: adaptive designs enabling planned interim analyses that can
60 lead to a reduction of the total number of randomized participants or to a deletion of
61 study arms with inefficient treatment regimens and re-randomization of subjects to the
62 more promising treatment arms; and external control arms that suppressed the need to
63 randomize participants to the ‘conventional treatment’.[4,5]

64 It is known that when a new treatment is being trialed, some patients will present the
65 event the treatment is supposed to prevent as opposed to the “responders” who will
66 show the expected reaction to treatment. Identification of responders is a timely and
67 challenging issue that remains poorly studied, mainly because it is difficult to predict
68 who responders and non-responders will be. But beyond the importance of identifying
69 responders in the era of personalized medicine, the consequences of enrolling non-
70 responders in RCTs remain unexplored.

71 The work presented here focus on the ethical issue arising from including non-
72 responders in RCTs. More precisely, the objective of our work is to show how can
73 RCT simulations be used to address the consequences on the researcher’s ethical
74 obligation of diluting the responders in the trial sample. Our simulations do not aim at
75 quantitatively defining adequate parameters of an RCT but intend to draw upon the
76 qualitative perception of the issue of ethical loss linked to the current way of RCTs
77 are planned, especially when it comes to eligibility criteria. To that extent, our
78 approach focuses on treatment efficacy.

79 **MATERIAL AND METHODS**

80 **Overview**

81 Collected data from a published trial was used for the simulations conducted for the
82 purpose of this study. The definitions of each category of trial participants defined
83 below were applied to allow for computing the required number of participants for the
84 five categories. Instead of applying the formula directly, we used a more intuitive
85 approach for the computations. The changes in different trial characteristics as a
86 function of the proportion of responders was explored, taking the published trial as
87 the point zero.

88 **Conceptual framework of this work**

89 *The two separate objectives of a clinical trial*

90 When one states that a trial is “aimed at demonstrating the efficacy of X in, for
91 example, preventing death in patients with type 2 diabetes”, the statement has two
92 intertwined meanings, or objectives, one being qualitative, the other quantitative.

93 First, it means that the trial is expected to show that X is more effective than the
94 control in preventing death (qualitative objective), and second, that it will provide an
95 estimate of the effect size (quantitative objective). The two objectives are tightly
96 intertwined because the achievement of the first one depends, among others, on the
97 observed effect size. However, for the sake of our reasoning, these must be strictly
98 separated, focusing on the number of responders (a quantitative objective). Although
99 out of the scope of the work developed here, there are other, more fundamental,
100 reasons for separating these two objectives. Just to name two examples: while the
101 efficacy is a treatment property, which supports consideration of extrapolating the
102 context of use, the validity of the effect size estimate based on the difference between
103 the observed rates of the event in the two arms is limited to the trial itself.

104 **'Responders' and 'non-responders'**

105 *Definition of a responder*

106 Let us assume that the expected effect of the treatment of interest is to prevent a
107 dichotomous (yes/no) event, such as death. In this instance, a responder is a patient
108 who would have presented the event the experimental therapy is supposed to prevent
109 if he/she had not been treated with this therapy, and who will not present it if treated
110 with the therapy. In a mortality, parallel-arm design, placebo-controlled RCT,
111 responders will be the subjects with a fatal outcome under placebo (P) administration
112 but who are kept alive if administered the experimental treatment (T). Although it
113 sounds simple, in practice, this definition is difficult to apply: how to predict that a
114 given patient is a responder? Note the assumption that the experimental treatment is
115 better than the reference, at least for a few participants, or even a single one.

116 *Number of responders in a two-arm RCT*

117 Let us use as an example a two-arm completed RCT with the number of event-free
118 subjects and participants having presented the event as shown in Table 1. At baseline,
119 the two study arms are supposed to be identical, thanks to randomization. Although in
120 the real world, the blind randomizing process is aimed at producing two groups
121 identical on average, we will assume that all subjects included in the trial display
122 similar baseline characteristics, i.e. are exchangeable.

123 The event rates are defined as $R_c = a/N_c$ and $R_T = b/N_T$ in the control and
124 experimental treatment groups, respectively. The experimental treatment efficacy is
125 measured by the absolute benefit, $AB = R_c - R_T$, but other efficacy metrics have been
126 also described.[6] A statistical test on the observed value of the chosen metrics
127 enables us to conclude on the materiality of the treatment efficacy. The metrics
128 absolute value and its corresponding confidence interval are used to translate the size
129 of the efficacy observed in the trial to a different setting.[6]

130 **Table 1.** Summary data of a completed RCT.

	Control arm	Experimental treatment arm
Event	a	b
No event	c	d
Total	N_c	N_T

131 *How many responders in an RCT?*

132 Should the experimental treatment be effective, this translates in a true R_c greater
133 than the true R_T . Moving forwards, observed values are assumed as the true values. In
134 the experimental treatment arm, there are responders, who encompass the difference
135 in magnitude of effect compared to the control arm. Since all subjects included in the
136 trial are assumed identical, there is a responder counterpart in the control arm.
137 Designated ‘potential’ responders, unlike responders in the experimental therapy arm,
138 they will not benefit from participating in the trial.

139 Since all participants are assumed exchangeable, they are in fact identical and we can
140 apply the definition of responders given above. According to that same definition, the
141 number of responders in the experimental therapy arm is given by $(R_c - R_T) \cdot N_T$. In
142 fact, they are among the ‘d’ participants in the experimental therapy arm who will not
143 develop the event (Table 1). The remaining of the ‘d’ patients are those who would
144 not have presented the event when not receiving the experimental treatment. The total
145 number of responders in the trial, i.e. the number of responders in the experimental
146 treatment arm plus the number of potential responders in the control arm, is $(R_c - R_T) \cdot$
147 $(N_c + N_T)$.

148 *How many non-responders in this RCT?*

149 According to our definition of responders, the non-responders are those subjects who
150 would experience the event regardless of being administered the experimental
151 treatment or not. Their number in the experimental treatment arm is ‘b’ and $a - (R_c -$
152 $R_T) \cdot N_c$ in the control group. Their total number is $(a + b) - (R_c - R_T) \cdot N_c$.

153 *Non-informative and unnecessary participants in a trial*

154 Let us deal first with the primary objective of a RCT, which is to generate evidence to
155 support the efficacy, i.e. reduces the rate of the event of interest, of the experimental
156 treatment that happens when the observed difference in rates $R_c - R_T$ is large enough
157 to rule out the play of chance. Looking at the figures in Table 1 from a purely
158 arithmetic point of view, the gold standard statistical significance can be achieved,
159 among other means, by decreasing ‘c’ and ‘d’, the number of recruited subjects who
160 will not present the event, whatever the arm they have been randomly allocated to.
161 These ‘c + d’ participants do not carry any information regarding the primary
162 objective of the trial. Their main “role” in the trial is to provide a denominator value
163 for computing the rates, R_c and R_T . As noted above, the responders in the treatment
164 arm are hidden in ‘d’. These $(R_c - R_T).N_T$ participants are in effect the only ones to
165 benefit from participating in the trial. Further, they carry the efficacy as captured in
166 the trial. For this reason alone, they must be counted apart. Participants $c + d - (R_c -$
167 $R_T).N_T$ are said “non-informative” for they do not contribute with real pharmacologic
168 effect from the experimental treatment. Elaborating on this same reasoning, the non-
169 responders are unnecessary participants for they do not bring into the trial a part of the
170 experimental treatment efficacy and they cannot (when they were allocated to the
171 control arm) or do not (experimental treatment arm) benefit from the treatment. In
172 fact, as shown later by the simulation, a ‘perfect’ trial does recruit only responders. In
173 total, the number of unnecessary participants in clinical trial is $(c + (d - R_T.N_T)) + (a +$
174 $b) - N_R$. Hence, we identified and defined four categories of participants in a trial, the
175 last category of which being the sum of the two previous ones (see Table 3):
176 responders, non-responders, non-informative and unnecessary participants, totaling
177 the number of non-responders and non-informative participants.

178 **Ethical losses and unnecessary participants**

179 A source of recurring dispute within RCTs is their ethical acceptability. For an
180 individual, participating in an RCT can mean different types of ethical loss, for
181 example, exposure to side-effects, loss of access to standard care, or loss of access to
182 the best available and tailored treatment. There are, of course, benefits: best care
183 administered for free, chance to be given a new, more effective treatment, to name a
184 few. However, given the diversity of individuals, it is impossible to ensure a positive
185 benefit-loss balance for each participant. There is, therefore, an ethical obligation to
186 minimize the number of participants enrolled for whom the benefit-loss balance
187 would be negative. When the outcome of interest is deemed serious or life-
188 threatening, and death is certainly the most serious one, the marginal benefits,
189 whatever they are, can be disregarded and ethical loss defined as any participant
190 enrolled in the trial who is not a responder. Therefore, the number of ethical losses is
191 $(N_c + N_T) - (R_c - R_T) \cdot N_T$.

192 *A simplified trial summary data*

193 A total of 7020 participants with type II diabetes were randomized to either placebo
194 (P) or empagliflozin (T) in the Empa-REG-Outcome trial.[7] In this trial, twice as
195 many participants were randomized to the experimental treatment arm compared to a
196 control arm. For the sake of simplicity, an assumption was made that the experimental
197 treatment had no other effect than preventing death, which was not the case in the
198 actual trial. And, instead of using the composite primary endpoint used in the original
199 trial, mortality from any cause was chosen, which is straightforward in its validity and

200 interpretation. Mortality figures in this simplified version of the original trial are
201 given in Table 2.[7]

202 **Table 2.** Mortality figures in the Empa-REG-Outcome Trial [7]

	Placebo	Treatment	Total
Deceased	194	269	463
Alive	2139	4418	6557
Total	2333	4687	7020

203 *Assumptions*

204 For the sake of simplicity, a first assumption was made that the probability of death of
205 non-responders was constant. This assumption does not apply in real life for a given
206 disease, the untreated outcome probability varies from one subject to another, thus
207 from one trial to another. Second, the only subgroup that remained the same in our
208 simulations was that of the responders in the experimental treatment arm, that is those
209 participants who benefited from having been enrolled in the trial.

210 *Simulations*

211 RCT simulations were carried out varying the proportion of responders. In contrast, as
212 said above, the number of participants in the subgroup of responders in the T arm was
213 kept constant (n=121, see below in the results section). It was assumed that, for
214 unnecessary participants, the “true” probability of death while untreated is the
215 observed death rate, R_c , in the control arm that remained constant across all simulated
216 trials. At each increment of the proportion of responders (0.025), a new RCT arises,
217 and the following values were computed from the new RCT’s summary data (Table

218 1): the number of ethical losses, trial sample size, observed relative risk (RR), and
219 chi-square value for testing drug efficacy. The starting proportion is 1, a value
220 corresponding to the “perfect” trial where all enrolled participants are responders (see
221 below). The final proportion is 0.025, since a proportion that equals 0 results in
222 infinite values. Note that the proportion of responders in the Empa-REG-Outcome
223 trial is 0.023. Computations were done using an Excel spreadsheet. The numerical
224 values of the participants were rounded to the closest unit.

225 RESULTS

226 *How many subjects per category are behind mortality information in the simplified*
227 *trial?*

228 One of the measures of efficacy in RCTs is the relative risk (RR); in our simplified
229 trial, derived from the Empa-REG-Outcome trial,[7] the RR was 0.73. The
230 information on treatment efficacy is entirely carried by the responders. The
231 responders do not appear as such in Table 2, and little derivation is required to bring
232 them off, which is explained below. Other derivations and categories of participants
233 enrolled in the trial are also developed below, and their results are shown in Table 3.
234 The number of expected deaths in the T group if the participant had not received the
235 experimental treatment is $(194 * (4687/2333)) = 390$. [7] Thus, the number of
236 responders in the T group is $390 - 269 = 121$, which is another way to compute the
237 number of responders than the one given by definition itself, $(R_C - R_T) \cdot N_T$. Since the
238 size of the P group is about half the size of the T group, there are potential 60
239 responders in the P group, who, by definition, are among the 194 participants in the P
240 group with fatal event, i.e. death. Consequently, a total number of 181 participants

241 (121 + 60) with a responder profile have been recruited in the Empa-REG-Outcome
242 trial, representing only 2.3% of the enrolled participants.

243 These 181 responders and potential responders have a counterpart, the non-
244 responders. This counterpart is defined as those subjects enrolled in the trial arm T for
245 whom the experimental treatment did not prevent death, i.e. all deceased participants
246 in the T arm (269), plus those participants in the P group for whom the experimental
247 treatment would not have prevented death, i.e. 134 (194 – 60). Note that participants
248 who stayed alive, whether treated or not, are neither responders nor non-responders,
249 and considered neutral regarding the drug efficacy. The total of unnecessary
250 participants equals $7020 - 181 = 6839$, while the ethical losses (i.e., all the
251 participants who do not benefit from enrolment in the trial regarding the primary
252 outcome) add up to a total $6839 + 60$, the potential responders in the P group. The
253 range of participant categories defined against response to drug T is shown in Table 3
254 below.

255 In this trial, all those participants who did not benefit from the experimental
256 treatment, 98.3% of all enrolled subjects, suffered ethical loss, i.e. 7020, minus the
257 number of responders in the T group, 121. Note that the degree of ethical loss depends
258 on the endpoints, with the maximum loss occurring if the endpoint is premature death.

259 **Table 3.** Demographic characteristics of participants.

Categories	Total N in the Empa-REG-outcome trial	Computation	Comments
Responders	181	121 (T group) +	In the T arm, the number of

		60 (P group)	responders is obtained by subtracting the observed number of deaths (269) from the expected number of deaths if T = P, $390 = 194 * (4687 / 2333)$; in the P group $60 = 121 * (2333 / 4687)$
Non-responders	403	269 (T group) + (194 – 60) (P group)	All deaths in T arm + all deaths in P arm minus the number of responders in the P arm.
Non-informative	6436	2139 (number of alive participants in the P group) + 4418 (number of alive participants in the T group) – 121 (responders in the treatment arm)	
Total of unnecessary participants	6839	6436 (non-informative) + 403 (non-responders)	This is the total number of participants minus the T responders (121) and potential responders (60)
Ethical losses	6899	6839 (total	Number equals to total sample size

		unnecessary participants) + 60 (the potential responders in the P group)	less the number of responders (the “true” responders, those participants who benefit from enrolment in the trial)
--	--	--	---

260 *Relations between the proportion of responders and trial characteristics*

261 Relations between the percentage of responders and outstanding trial features (i.e.,
262 ethical losses, trial sample size, observed relative risk, and chi-square value for testing
263 drug efficacy) are shown in Figure 1 below. All other things being equal, especially
264 the responders and non-informative subject profiles, when the percentage of
265 responders in the trial sample increases from null to 100% (the “perfect” trial sample),
266 the ethical losses, the sample size, thus the overall trial cost, the observed relative risk
267 decrease, while the chi-square value increases. Since the sample size decreases, the
268 overall trial cost decreases, while the chi-square value increases, also increasing the
269 chance of demonstrating the experimental treatment’s efficacy. The overall
270 conclusion from these results supports the intuitive conviction that efficacy is less
271 likely demonstrable when responders are insufficiently represented in the trial sample.

272 **Figure 1.** Relations between the proportion of responders in the trial sample and
273 major features of the trial.

274 *The “perfect” randomized clinical trial*

275 Were it possible to recruit only responders, this amounts to the perfect RCT: i) all
276 treated participants who otherwise would have died will be alive by the end of the

277 trial; ii) the number of subjects needed to achieve the sample size for randomization
278 would be the lowest possible; iii) the ethical losses minimized. Here the ethical losses
279 amount to 60 (33.4%) of all randomized subjects (Table 4). We notice that even in
280 this “perfect” RCT, there is an inescapable, although minimized, ethical loss.

281 **Table 4.** Ethical losses

	P	T	
Deceased	60	0	60
Alive	0	121	121
	60	121	181

282 *“Less perfect” trials*

283 No matter how much we would like it to happen, identifying responders with 100%
284 accuracy is nothing but a pipe dream. Among the many reasons for this is the simple
285 fact that the drug has not yet been tested in humans in the anticipated context of use in
286 real life, preventing any researcher from inferring the responder profile. However,
287 while work is ongoing to overcome this hurdle and identify responders’ profile ahead
288 of the trial as accurately as possible, we explored the consequences of progressively
289 increasing the proportion of responders in our simulated example in Figure 1,
290 showing that ethical losses, the required trial sample size and the relative risk all
291 decrease, while the probability of ascertaining trial significance increases.

292 **DISCUSSION**

293 The results and their derivation share a series of disruptive points that deserve
294 discussion.

295 **Ambiguity of clinical trial objectives**

296 A trial said to be “aimed at demonstrating the efficacy of X on preventing death in
297 patients with type 2 diabetes”, has two intertwined meanings. First, the trial is
298 expected to show that X is more effective than the control, and second, that it will
299 provide an estimate of the effect size. We have shown that observed efficacy in the
300 trial and therefore the chance to demonstrate efficacy is dependent on the proportion
301 of responders, whereas the genuine efficacy of the experimental treatment is a
302 property that is independent of this proportion.

303 *Is treatment efficacy carried by responders in full?*

304 Traditionally, response to treatment and the treatment effect size are the cornerstones
305 of efficacy demonstration for any RCT. Such assumptions have two major
306 consequences. First, efficacy is diluted across the entire sample of participants. By
307 applying the responder paradigm, as shown here, efficacy is no longer diluted. For the
308 recruited subjects, the tested treatment is or is not effective, it is a dichotomous
309 (yes/no) response. While such a way of looking at efficacy is acceptable for a binary
310 event such as death or relapse of HBV infection, for example, it seems less relevant
311 for a continuous outcome such as pain. However, even pain can be binarized if we
312 take into account each participant's own threshold of pain acceptability. Second,
313 translation to other populations is often achieved by applying the measured relative
314 risk. With this responder paradigm, efficacy indices obtained on one population are
315 irrelevant to another population (see panel C, Figure 1) because it is likely that the
316 fraction of responders will vary between populations, and so will the relative risk and
317 all other indices. The point here is that the proportion of subjects not at risk and
318 responders randomized in either arm will change, and thus the relative risk will

319 change accordingly. This is a consequence of the Effect Model (EM) law, a principle
320 that has been verified both empirically and theoretically.[8] The EM law says that the
321 absolute benefit in a population varies as a function of individual or sub-group rate of
322 events (R_c), whatever is the treatment of interest. Therefore, both R_t and R_c vary, and
323 so does the relative risk. The relative risk remains constant in one instance only: when
324 the EM is linear, which seems quite infrequent.

325 *Non-informative or unnecessary participant = ethical loss; how does the equation*
326 *fare?*

327 Central in the argumentation is the idea that data on efficacy in an RCT is only carried
328 by the responders. This proportion of responders is the taproot of the ethical losses
329 since, for those who are not responders, the burden of participating in a trial is not
330 offset by the benefit expected.

331 *Is focusing on the unnecessary trial participants a way to address ethical issues in*
332 *an RCT?*

333 The uncertainty which raises when enrolling in an RCT has two opposite bases. On
334 the one hand, the standard treatment is possibly less effective or more harmful than
335 the experimental treatment. On the other, the standard treatment is known to be
336 effective, whereas the new one's efficacy is only postulated. To help handle the two
337 opposite uncertainties, Freedman proposed the concept of "equipoise".[9] An
338 investigator can enroll subjects in an RCT if there is genuine uncertainty about the
339 preferable treatment.[10] It is interesting to note that in a review of childhood
340 oncology trials, the odds ratio for survival was 0.96, suggesting that the equipoise has
341 been respected.[11] This finding points out to a limitation of this equipoise principle:

342 is it ethical to launch a trial if the evidence in favor of an expected superior efficacy of
343 the experimental treatment against the control is almost nil? Identifying responders
344 would in fact reduce uncertainty and can be viewed as an operational equipoise
345 principle.

346 *Is the “perfect” RCT “fully” ethical?*

347 When we considered the “perfect” RCT, with 100% of responders, we noted that the
348 60 participants randomized to the control arm, had all deceased by the end of the trial:
349 the ethical loss for this “perfect” RCT was 33%. Thus, even a perfect randomized trial
350 cannot annul the number of unnecessary participants. This fact deserves three
351 comments: i) the ethical loss can be reduced by lowering the fraction of subjects
352 randomized into the control arm; ii) however, the ethical loss in a RCT cannot be
353 avoided; iii) increasing the proportion of responders implies that a reliable tool is
354 required to enable their selection.

355 Other ethical issues remain for responders such as the amount and type (e.g., invasive
356 investigations) of data collected, number of investigation time-points, confidentiality,
357 and informed consent process.

358 *Selection of responders for enrolment in RCT: neither new nor easy*

359 Sequential designs were long proposed to reduce the number of subjects enrolled.
360 [12,13] Increasing the proportion of responders is one of the arguments in favor of
361 adaptive designs.[4] But the issue remains, how to select responders ahead of trial
362 onset or more often during the trial. Several ways have been explored: responders
363 identified with markers of response,[14] good compliers as assessed in a run-in

364 phase,[15] play-the-winner,[16] discontinuation for non-responders or considerably
365 improved participants in a run-in phase,[17] post-hoc selection, for instance, non-
366 responders discontinuation trial designs.[18] All these attempts have not been widely
367 adopted either because they were not proven successful, or because they are difficult
368 to implement or because they were considered unethical.[19]

369 A tool that can identify responders before enrolment is clearly needed. More
370 specifically, the false positive error rate must be 0. We are still far from achieving
371 fully reliable tools, although hints as to whether they could be designed are now
372 available.[20] Nevertheless, if this is achieved, the permanence of RCT as the gold
373 standard will be more strongly and more rightly challenged.

374 **Conclusion**

375 The simulation reported here confirms that increasing the proportion of responders in
376 a RCT is worthwhile on ethical grounds, mainly because it reduces the number of
377 subjects enrolled who do not provide information on treatment efficacy.

378 We claim that the low proportion of responders is parallel to and a marker of the
379 uncertainty relating to the experimental treatment efficacy ahead of trialing new
380 drugs. Scannel and Bosley have shown that, currently, drug development processes
381 are poorly informative.[21] According to new policies issued by the FDA and EMA,
382 performing *in silico* clinical trials might be a solution to improve the efficiency of
383 R&D by reducing uncertainty across all the stages.[22-24] Individualized computer
384 simulations could become therefore a valuable tool to identify responders ahead of
385 designing RCT.[8,25]

386 **FUNDING STATEMENT**

387 This work was supported by RESSTORE project (www.resstore.eu) funded by the
388 European Commission under the H2020 program (Grant Number 681044). Authors
389 are independent of the funder.

390 Ethical approval was not required, and no patients have been involved.

391 Data resulting from simulations are open access.

392 **COMPETING INTEREST STATEMENT**

393 All authors have completed the Unified Competing Interest form (available on request
394 from the corresponding author) and declare: no support from any organization for the
395 submitted work [or describe if any]; no financial relationships with any organizations
396 that might have an interest in the submitted work in the previous three years [or
397 describe if any], no other relationships or activities that could appear to have
398 influenced the submitted work [or describe if any].

399 **AUTHOR CONTRIBUTIONS**

400 As the guarantor of the study, Jean-Pierre Boissel contributed to the
401 conceptualization, data curation, formal analysis and software as well as the
402 development of the methodology and the original draft preparation. He also
403 contributed, together with Marc Hommel, Ingrid Klingmann and David Pérol, to the
404 management and coordination of the research activity planning and activation. Marc
405 Hommel was responsible for the funding acquisition. All authors contributed equally

406 to the validation, visualization, and review and editing of the manuscript submitted
407 for publication.

408 **ACKNOWLEDGMENTS**

409 The authors thank Rita Moreira da Silva and Paulo Pacheco for their contribution to
410 the editing and formatting of the manuscript.

411

412 **REFERENCES**

- 413 1. Saad ED, Paoletti X, Burzykowski T, Buyse M. Precision medicine needs
414 randomized clinical trials. *Nat Rev Clin Oncol.* 2017;14: 317–23. doi:
415 10.1038/nrclinonc.2017.8.
- 416 2. van Rosmalen BV, Alldinger I, Cieslak KP, Wennink R, Clarke M, Ali UA, et al.
417 Worldwide trends in volume and quality of published protocols of randomized
418 controlled trials. *PLoS One.* 2017;12: e0173042. doi: 10.1371/journal.pone.0173042.
- 419 3. Levine R, Lebacqz, K. Some ethical considerations in clinical trials. *Clin*
420 *Pharmacol Ther.* 1979;25: 728–41.
- 421 4. Brown CH, Have TRT, Jo B, Dagne G, Wyman PA, Muthén B, et al. Adaptive
422 designs for randomized trials in public health. *Annu Rev Public Health.* 2009;30: 1–
423 25. doi: 10.1146/annurev.publhealth.031308.100223.
- 424 5. Thorlund K, Dron L, Park JJH, Mills EJ. Synthetic and External Controls in
425 Clinical Trials – A Primer for Researchers. *Clin Epidemiol.* 2020;12: 457–467. doi:
426 10.2147/CLEP.S242097.
- 427 6. Boissel JP, Cogny F, Marko N, Boissel FH. From Clinical Trial Efficacy to Real-
428 Life Effectiveness: Why Conventional Metrics do not Work. *Drugs Real World*
429 *Outcomes.* 2019;6: 125–32. doi: 10.1007/s40801-019-0159-z.
- 430 7. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
431 Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J*
432 *Med.* 2015;373: 2117–28. doi: 10.1056/NEJMoa1504720.

- 433 8. Boissel JP, Cucherat M, Nony P, Chabaud S, Gueyffier F, Wright JM, et al. New
434 insights on the relation between untreated and treated outcomes for a given therapy
435 effect model is not necessarily linear. *J Clin Epidemiol.* 2008;61: 301–7. doi:
436 10.1016/j.jclinepi.2007.07.007.
- 437 9. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med.*
438 1987;317: 141–5 doi: 10.1056/NEJM198707163170304.
- 439 10. Djulbegovic B. Acknowledgment of uncertainty: a fundamental means to ensure
440 scientific and ethical validity in clinical research. *Curr Oncol Rep.* 2001;3: 389–95.
441 doi: 10.1007/s11912-001-0024-5.
- 442 11. Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, et al; Children's
443 Oncology Group. Are experimental treatments for cancer in children superior to
444 established treatments? Observational study of randomised controlled trials by the
445 Children's Oncology Group. *BMJ.* 2005;331: 1295. doi:
446 10.1136/bmj.38628.561123.7C.
- 447 12. Berry SM, Broglio KR, Groshen S, Berry DA. Bayesian hierarchical modelling of
448 patient subpopulations: Efficient designs of Phase II oncology clinical trials. *Clin*
449 *Trials.* 2013;10: 720–34. doi: 10.1177/1740774513497539.
- 450 13. Whitehead J. A unified theory for sequential clinical trials. *Stat Med.* 1999;18:
451 2271–86. doi: 10.1002/(sici)1097-0258(19990915/30)18:17/18<2271::aid-
452 sim254>3.0.co;2-z.
- 453 14. Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M, et al.
454 Comprehensive screening of target molecules by next-generation sequencing in

- 455 patients with malignant solid tumors: guiding entry into phase I clinical trials. *Mol*
456 *Cancer*. 2016;15: 73. doi: 10.1186/s12943-016-0553-z.
- 457 15. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of
458 the run-in on the power of the Physicians' Health Study. *Stat Med*. 1991;10: 1585–93
459 doi: 10.1002/sim.4780101010.
- 460 16. Rosenberger W. Randomized play-the-winner clinical trials: review and
461 recommendations. *Control Clin Trials*. 1999;20: 328–42 doi: 10.1016/s0197-
462 2456(99)00013-6.
- 463 17. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase
464 II placebo-controlled randomized discontinuation trial of sorafenib in patients with
465 metastatic renal cell carcinoma. *J Clin Oncol*. 2006; 24: 2505–12. doi:
466 10.1200/JCO.2005.03.6723.
- 467 18. Park JW, Liu MC, Yee D, Yau C, van't Veer LJ, Symmans WF, et al. Adaptive
468 Randomization of Neratinib in Early Breast Cancer. 2016;375: 11–22. doi:
469 10.1056/NEJMoa1513750.
- 470 19. Coffey CS, Levin B, Clark C, Timmerman C, Wittes J, Gilbert P, et al. Overview,
471 hurdles, and future work in adaptive designs: perspectives from a National Institutes
472 of Health-funded workshop. *Clin Trials*. 2012;9: 671–80 doi:
473 10.1177/1740774512461859.
- 474 20. Boissel JP, Kahoul R, Marin D, Boissel FH. Effect model law: an approach for the
475 implementation of personalized medicine. *J. Pers Med*. 2013;3: 177–90. doi:
476 10.3390/jpm3030177.

- 477 21. Scannell JW, Bosley J. When Quality Beats Quantity: Decision Theory, Drug
478 Discovery, and the Reproducibility Crisis. *PLoS One*. 2016;11: e0147215. doi:
479 10.1371/journal.pone.0147215.
- 480 22. Model Informed Drug Development Pilot Program. Available from:
481 [https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/uc](https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm600311.htm)
482 [m600311.htm](https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm600311.htm).
- 483 23. Madabushi R, Benjamin JM, Grewal R, Pacanowski MA, Strauss DG, Wang Y,
484 Zhu H, Zineh I. The US Food and Drug Administration's Model-Informed Drug
485 Development Paired Meeting Pilot Program: Early Experience and Impact. *Clin*
486 *Pharmacol Ther*. 2019;106: 74–8. doi: 10.1002/cpt.1457.
- 487 24. Musuamba FT, Bursi R, Manolis E, Karlsson K, Kulesza A, Courcelles E, Boissel
488 JP, Lesage R, Crozatier C, Voisin EM, Rousseau CF, Marchal T, Alessandrello R,
489 Geris L. Verifying and Validating Quantitative Systems Pharmacology and In Silico
490 Models in Drug Development: Current Needs, Gaps, and Challenges. *CPT*
491 *Pharmacometrics Syst Pharmacol*. 2020;9: 195–97. doi: 10.1002/psp4.12504.
- 492 25. Viceconti M, Henney A, Morley-Fletcher E. In silico Clinical trials: how
493 computer simulation will transform the biomedical industry. *Int J Clin Trials*. 2016;3:
494 37–46. doi:10.13140/RG.2.1.2756.6164.

Figure 1 panel A




Figure 1 panel B




Figure 1 panel C




Figure 1 panel D




Figure 1 Relations between the proportion of responders in the trial sample and major features of the trial

Panel A, shows the linear decrease of the ethical losses expressed in percentage of unnecessary patients with the increase of the percentage of responders. Panel B, keeping the number of responders in the T group constant at $n=121$, the sample size drops abruptly from more than 7,000 to less than 1,000 when the responder percentage increases up to about 20% to then flatten until the “perfect” trial status is reached, meaning that only responders are enrolled. Panel C, the relative risk decreases rapidly until the responder percentage reaches about 40%, from less than 0.8 to about 0. Panel D, the chi-square value of the comparison test of mortality rates between placebo and treatment groups increases linearly as the percentage of responders increases. The probability of ascertaining significance increases as well.